Conditions: Contraception
Keywords: contraception intrauterine long-term reversible
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 1910
Healthy volunteers: yes

Brief summary:
The primary objective of this study is to assess the efficacy of a levonorgestrel-releasing intrauterine system (LNG20) in nulliparous and parous females of child-bearing potential who request long-term, reversible contraception for up to 10 years.

Detailed description:
This is a Phase 3, randomized, open-label, multicenter evaluation of the efficacy of a levonorgestrel-releasing intrauterine system (LNG20). The goals of the study include provision of information to understand efficacy and safety within the widest range of possible users of the LNG20. Typically, intrauterine contraceptive studies only include women 18-35 years of age for efficacy and safety, and place limits on parity and larger body size. Women outside of these characteristics also desire an effective intrauterine contraceptive. Accordingly, this study will include women who are both nulliparous and parous as well as women less than 18 years of age in the primary efficacy and safety analyses

Arms:
arm 1: LNG20 levonorgestrel-releasing intrauterine system in subjects 16-35 years of age arm 2: Levonorgestrel-releasing intrauterine system for contraception arm 3: LNG20 levonorgestrel-releasing intrauterine system in subjects 36-45 years of age

Interventions: intervention 1: LNG20 intervention 2: Mirena
Intervention descriptions: intervention 1: levonorgestrel-releasing intrauterine system for contraception intervention 2: Mirena intrauterine system

Protocol document:
Prot_000.pdf: 
















 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
  
  
 
 
 
 
 
 
 
 
  
  
 
 
 
 
  
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
  
 
 
  
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
  
 
 
 
 
 
 
  
 
 
 
 
 
  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
  
 
 
 
  
 
 
 
 
 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 














































































































































































Medicines360 
LNG20 
Clinical Study Protocol 
M360-L1O2 
Walsh T, Grimes D, Frezieres R, Nelson A, Bernstein L, Coulson A, et al. Randomized 
controlled trial of prophylactic antibiotics before insertion of intrauterine devices. Lancet 
1998;35 l: 1005-8. 
Wu JP, Pickle S. Extended use of the intrauterine device: a literature review and 
recommendations for clinical practice. Contraception 2014;89:495-503. 
Version 9.0 
CONFIDENTIAL 
Retrieved from the Medicines360 Veeva EDMS on 21 Sep 2023 by 
Page 96 of 108 




















Medicines360 
LNG20 
Protocol Synopsis 
Changed Planned Study Dates 
Planned Study 
Dates, Duration of 
Subject 
Participation, 
Duration of Study 
Center 
Participation, 
Protocol Section 2 
Protocol Synopsis 
Study Design, 
Protocol Section 
3.1, 6.4 
Protocol Synopsis 
Study Design, 
Dosing Regimen, 
Protocol Sections 
3.1, 5, 6.6 
Protocol Synopsis 
Study Design, 
Other Secondary 
Outcome Measures, 
Protocol Sections 
2.2, 3.1, 3.2.3, 
4.4.3, 6.10.3 
Protocol Synopsis 
Key Secondary 
Outcome Measures, 
Statistical Methods, 
Protocol Sections 
3.2.2, 9.1, 9.8 
Added study assessments at Months 102, 108, 1 14, 
120, 121 
Added treatment discontinuation for LNG20 16-35 
year old subjects at Month 121 and for LNG20 16-35 
year old subjects at Month 96 
Levonorgestrel sampling after IUS removal revised to 
start at Month 121 
Added years 8, 9 and 10 to efficacy determination 
Removed requirement for acceptable Pearl Index 
Version 9.0 
CONFIDENTIAL 
Clinical Study Protocol 
M360-L 102 
Extension of the protocol intended duration of use 
from 8 years to 10 years 
Extension of the protocol intended duration of use 
from 8 years to l O years 
Extension of the protocol intended duration of use 
from 8 years to 10 years for LNG20 subjects only. 
Month 121 added to ensure a complete duration of 
use through IO years. Discontinuing LNG20 36-45 
year old enrollment group at 8 years because their 
age at discontinuation will be 43 to 53 years old and 
therefore unlikel to re uire contrace tion. 
Extension of the protocol intended duration of use 
from 8 years to 10 years 
Extension of the protocol intended duration of use 
from 8 years to 10 years 
Page 106 of 108 
Retrieved from theMedicines360 Veeva EDMS on 21 Sep 2023 by 


Medicines360 
LNG20 
Protocol Synopsis 
Revised cumulative pregnancy rates to be determined 
Other Secondary 
through year 10 
Outcome Measures, Added years 9 and 10 for LNG20 subjects only for 
Protocol Sections 
3.2.3, 9.9 
IUS continuation rates, IUS expulsion rates and IUS 
safety-related removal rates 
Protocol Synopsis 
Revised sample size 
Sample Size, 
Protocol Section 
9.1 
Protocol Section 
Revised approved duration of use for Liletta® from 3 
1.1.1 
to 4 years 
Protocol Section 
Revised Bleeding/Cramping F onn, hemoglobin, 
6.4 
plasma levonorgestrel collection visits and breast 
exam, pelvic exam, Pap testing and STD testing 
schedule 
Protocol Section 
Added study contacts at Months 99, 105, 111 and 
6.5 
117, and revised Bleeding/Cramping Form collection 
visits 
Added contact with LNG20 subjects approaching 
Year 10 discontinuation to notify them of option of 
extending use to 1 O years 
Protocol Section 
Added summary of release rate data of LNG20 
7.1. l 
projected to 10 years 
Protocol Section 
Revised bleeding/cramping form completion duration 
7.12.1 
to 121 months 
Protocol Section 
Increased dropout rate 
9.1 
Version 9.0 
CONFIDENTIAL 
Clinical Study Protocol 
M360-L 102 
Extension of the protocol intended duration of use 
from 8 years to l O years 
Extension of the protocol intended duration of use 
from 8 years to 10 years 
Extension of the protocol intended duration of use 
from 8 years to 10 years with concomitant additional 
subject dropouts 
Liletta (LNG20) approved for extension to 4 years 
of use in 2017 
Extension of the protocol intended duration of use 
from 8 years to 10 years 
Extension of the protocol intended duration of use 
from 8 years to 10 years 
Extension of the protocol intended duration of use 
from 8 years to 10 years 
Provided to assess the risk of pregnancy beyond 8 
years due to extension of the study to l O years 
duration of use 
Extension of the protocol intended duration of use 
from 8 years to IO years 
Extension of the protocol intended duration of use 
from 8 vears to 10 vears 
Page 107 of 108 
Retrieved from the Medicines360 Veeva EDMS on 21 Sep 2023 by 


Medicines360 
LNG20 
Protocol Section l 1 
Added references 
Appendix A, 
Revised Schedule of Events 
Schedule of Events 
Version 9.0 
CONFIDENTIAL 
Clinical Study Protocol 
M360-L102 
Additional references provided for Section 7 .1.1 
Additional time points and events were added to 
extend the study to IO years duration of use for 
LNG20 16-35 year olds and discontinue LNG20 36-
45 year olds at 8 years duration of use 
Page 108 of 108 
Retrieved from theMedicines360 Veeva EDMS on 21 Sep 2023 by 

SAP_001.pdf: 
Page 1 of 38 
Statistical Analysis Plan 
Medicines360 
Protocol: M360-L102 
A Phase 3, Multi-Center, Open-Label Study of a Levonorgestrel-Releasing Intrauterine 
System for Long-Term, Reversible Contraception  
Protocol Version: Version 9.0, dated 02 October 2017 
Medicines360: 
Medicines360 
Prepared by: 
Version: 
4.0  
Version 1.0 Date: 
06 September 2012 
Version 2.0 Date: 
20 February 2013 
Version 3.0 Date: 
26 May 2016 
Version 4.0 Date: 
02 October 2017 
Retrieved from the Medicines360 Veeva EDMS on 27 Sep 2023 by 


Medicines360 
  Statistical Analysis Plan 
M360-L102 
02 October 2017 
Page 2 of 38 
TABLE OF CONTENTS 
LIST OF ABBREVIATIONS ....................................................................................................... 4 
DEFINITIONS ............................................................................................................................... 6 
1.
INTRODUCTION .................................................................................................................. 8 
2.
STUDY OBJECTIVES .......................................................................................................... 8 
2.1 
PRIMARY OBJECTIVE ..................................................................................................... 8 
2.2 
SECONDARY OBJECTIVES .............................................................................................. 8 
3.
STUDY DESIGN AND PLAN .............................................................................................. 9 
4.
DETERMINATION OF SAMPLE SIZE .......................................................................... 12 
5.
GENERAL ANALYSIS CONSIDERATIONS ................................................................. 13 
5.1 
DATA SUMMARIES ....................................................................................................... 13 
5.2 
DATA HANDLING ......................................................................................................... 14 
5.2.1 
Conventions .................................................................................................... 14 
5.2.2 
Unscheduled Visits ......................................................................................... 14 
5.3 
HANDLING OF DROPOUTS OR MISSING DATA ............................................................. 14 
5.3.1 
Diary Data ...................................................................................................... 15 
5.3.2 
Bleeding, Cramping, and Other Contraceptive Use ....................................... 16 
5.3.3 
Missing Adverse Event Start and Stop Dates ................................................. 16 
5.3.4 
Missing Concomitant Medication Start and Stop Dates ................................. 17 
5.3.5 
Missing Dates for Other Events, Including Return to Menses, Return to 
Fertility, Pap Tests, Date of IUS Expulsion/Removal, and Reported Pregnancies ..... 17 
5.4 
STANDARD CALCULATIONS ......................................................................................... 18 
5.5 
28-DAY CYCLES OF USE CALCULATION FOR EFFICACY EVALUATION ....................... 19 
5.6 
MULTIPLE COMPARISON/MULTIPLICITY ..................................................................... 20 
5.7 
INTERIM ANALYSIS AND DATA MONITORING ............................................................. 20 
5.6.1 
Interim Analyses ............................................................................................. 20 
5.6.2 
Data Monitoring Committee ........................................................................... 20 
5.8 
MULTICENTER STUDIES ............................................................................................... 21 
5.9 
SUBGROUP ANALYSES ................................................................................................. 21 
6.
ANALYSIS POPULATIONS .............................................................................................. 21 
7.
STUDY POPULATION SUMMARIES ............................................................................. 22 
7.1 
SUBJECT DISPOSITION.................................................................................................. 22 
7.2 
PROTOCOL DEVIATIONS .............................................................................................. 22 
7.3 
DEMOGRAPHIC AND BASELINE CHARACTERISTICS ..................................................... 22 
8.
TREATMENT AND MEDICATION ................................................................................ 23 
8.1 
PRE-TRIAL AND CONCOMITANT MEDICATIONS ........................................................... 23 
8.2 
EXTENT OF EXPOSURE ................................................................................................. 23 
9.
EFFICACY ANALYSES ..................................................................................................... 23 
Retrieved from the Medicines360 Veeva EDMS on 27 Sep 2023 by 


Medicines360 
  Statistical Analysis Plan 
M360-L102 
02 October 2017 
Page 3 of 38 
9.1 
PREGNANCY ON STUDY ............................................................................................... 24 
9.2 
PRIMARY EFFICACY VARIABLE ................................................................................... 24 
9.3 
SECONDARY EFFICACY VARIABLES ............................................................................ 25 
9.4 
SECONDARY EFFICACY EVALUATIONS FOR PRE-SPECIFIED SUBGROUPS ................... 26 
10. METHODS OF EFFICACY ANALYSIS .......................................................................... 26 
10.1 PRIMARY EFFICACY ANALYSES .................................................................................. 26 
10.2 SECONDARY EFFICACY ANALYSES ............................................................................. 27 
10.2.1 Pearl Indices ................................................................................................... 27 
10.2.2 Pregnancy Rates ............................................................................................. 27 
10.3 PHARMACOKINETIC ANALYSES ................................................................................... 27 
10.3.1 Plasma Concentrations during IUS Use ......................................................... 27 
10.3.2 Pharmacokinetic Parameters during IUS Use ................................................. 28 
10.3.3 Elimination PK ............................................................................................... 28 
10.4 IUS ANALYSIS POST-REMOVAL .................................................................................. 28 
11. SAFETY ANALYSIS ........................................................................................................... 29 
11.1 PREGNANCY OUTCOMES.............................................................................................. 29 
11.2 ADVERSE EVENTS ........................................................................................................ 29 
11.3 INSERTION AND REMOVAL RELATED BLEEDING AND CRAMPING/PAIN ..................... 30 
11.4 MENSTRUAL RELATED CRAMPING/PAIN ..................................................................... 31 
11.4.1 Up to Month 24............................................................................................... 31 
11.4.2 After Month 24 ............................................................................................... 31 
11.5 MENSTRUAL RELATED BLEEDING ............................................................................... 32 
11.5.1 Up to Month 24............................................................................................... 32 
11.5.2 After Month 24 ............................................................................................... 32 
11.6 DIARY REPORTED BLEEDING AND CRAMPING/PAIN ANALYSIS.................................. 32 
11.6.1 Months 1-24 .................................................................................................... 32 
11.6.2 After Month 24 ............................................................................................... 33 
11.7 SITE DIARIES ................................................................................................................ 34 
11.8 INSERTION .................................................................................................................... 34 
11.9 CONTINUATION, EXPULSION, AND REMOVAL RATES .................................................. 35 
11.10 FERTILITY RATES POST-REMOVAL ............................................................................. 35 
11.11 RETURN TO MENSES .................................................................................................... 35 
11.12 PELVIC AND BREAST EXAMINATIONS ......................................................................... 36 
11.13 CLINICAL LABORATORY EVALUATION ....................................................................... 36 
11.13.1 Hemoglobin .................................................................................................... 36 
11.13.2 Chlamydia and Gonorrhea Evaluations .......................................................... 36 
11.13.3 Pap Tests ......................................................................................................... 36 
11.13.4 Serum Chemistry and Urine Pregnancy Tests ................................................ 36 
11.14 ENDOMETRIAL THICKNESS .......................................................................................... 36 
11.15 VITAL SIGNS ................................................................................................................ 37 
12. REFERENCES ..................................................................................................................... 38 
Retrieved from the Medicines360 Veeva EDMS on 27 Sep 2023 by 


Medicines360 
Statistical Analysis Plan 
M360-L102 
02 October 2017 
Page 4 of 38 
LIST OF ABBREVIATIONS 
AE 
adverse event 
ANCOVA 
analysis of covariance 
AR1 
first-order autoregressive 
ATC 
Anatomical Therapeutic Chemical 
BLQ 
below the level of quantification 
BMI 
body mass index 
BP 
blood pressure 
CI 
confidence interval 
cm 
centimeter(s) 
CM 
Concomitant Medication 
CRF 
case report form 
CS 
clinically significant 
CSR 
clinical study report 
DDE 
drug dictionary enhanced 
DRUP 
FDA Division of Reproductive and Urological Products 
EP 
Ectopic pregnancy 
ET 
endometrial thickness 
g 
gram(s) 
HEENT 
head, eye, ear, nose, and throat 
IDMC 
Independent Data Monitoring Committee 
in 
inch(es) 
IUS 
intrauterine system 
kg 
kilogram(s) 
lb 
pound(s) 
l 
Liter 
LNG 
Levonorgestrel 
LS 
least-square 
MedDRA 
Medical Dictionary for Regulatory Activities 
Mg 
milligram(s) 
MITT 
Modified Intent-to-Treat 
NDA 
new drug application 
Retrieved from the Medicines360 Veeva EDMS on 27 Sep 2023 by 


Medicines360 
Statistical Analysis Plan 
M360-L102 
02 October 2017 
Page 5 of 38 
LIST OF ABBREVIATIONS (continued) 
Ng 
nanogram 
PK 
Pharmacokinetics 
PP 
Per-Protocol 
RTF 
rich text format 
SAE 
serious adverse event 
SAP 
statistical analysis plan 
SAS 
SAS® Software 
SD 
standard deviation 
SE 
standard error 
TEAE 
treatment-emergent adverse event 
WHO 
World Health Organization 
WY 
Woman Years 
Retrieved from the Medicines360 Veeva EDMS on 27 Sep 2023 by 


Medicines360 
Statistical Analysis Plan 
M360-L102 
02 October 2017 
Page 6 of 38 
DEFINITIONS 
Adverse Event (AE) 
An adverse event is any untoward medical occurrence in 
a patient or clinical investigation subject administered a 
pharmaceutical product and which does not necessarily 
have to have a causal relationship with this treatment.  
An AE can, therefore, be any unfavorable and 
unintended sign (that could include a clinically 
significant abnormal laboratory finding), symptom, or 
disease temporally associated with the use of a medicinal 
product, whether or not considered related to the 
medicinal product.   
Data cut-off 
Includes all data with a date of occurrence up to and 
including the data cut-off date. 
Modified Intent-to-Treat 
(MITT) Population 
All subjects between 16 and 35 years of age at study 
entry for whom the assigned IUS is successfully placed 
in the uterus and for whom there is at least one 
assessment of pregnancy status after inserting the IUS. 
Per-Protocol (PP) 
Population  
A subset of the MITT population excluding subjects with 
major protocol deviations, to be identified prior to data 
cut-off. 
Safety Population 
All subjects enrolled who underwent the IUS insertion 
procedure, regardless of age and outcome. 
Serious Adverse Event 
(SAE) 
An adverse event that results in any of the following 
outcomes: death; life-threatening situation (subject is at 
immediate risk of death); inpatient hospitalization or 
prolongation of existing hospitalization; persistent or 
significant disability/incapacity;  congenital 
anomaly/birth defect in the offspring of a subject who 
received study drug; important medical events that may 
not result in death, be immediately life-threatening, or 
require hospitalization, may be considered an SAE when, 
based upon appropriate medical judgment, they may 
jeopardize the subject and may require medical or 
surgical intervention to prevent one of the outcomes 
listed in this definition.  
Retrieved from the Medicines360 Veeva EDMS on 27 Sep 2023 by 


Medicines360 
Statistical Analysis Plan 
M360-L102 
02 October 2017 
Page 7 of 38 
Treatment-Emergent AE 
(TEAE) 
AEs occurring during or after attempted IUS insertion 
and those pre-attempted IUS insertion existing medical 
conditions that worsened during the study up to the 
subject's last known IUS date of use or, for subjects who 
have discontinued, through 30 days after the subject's 
last known IUS date of use. 
Retrieved from the Medicines360 Veeva EDMS on 27 Sep 2023 by 


Medicines360 
Statistical Analysis Plan 
M360-L102 
02 October 2017 
Page 8 of 38 
1.
INTRODUCTION
This document outlines the statistical methods to be implemented during the analyses of 
data collected within the scope of Medicines360, Protocol M360-L102 [A Phase 3, Multi-
Center, Open-Label Study of a Levonorgestrel-Releasing Intrauterine System for Long-
Term, Reversible Contraception].  The purpose of this plan is to provide specific 
guidelines from which the analysis will proceed.  Any deviations from these guidelines 
will be documented in the clinical study report (CSR).  In the event where discrepancies 
in statistical analysis may be encountered between the SAP and what is described in the 
study protocol, the SAP will take precedence. 
2.
STUDY OBJECTIVES
This study is being performed to evaluate the Medicines360 levonorgestrel-releasing 
IUS, LNG20.  LNG20 is expected to provide safe and effective contraception for up to 10 
years. 
2.1 Primary Objective 
The primary objective of this study is to assess the efficacy of a levonorgestrel-releasing 
intrauterine system (LNG20) in nulliparous and parous females of child-bearing potential 
who request long-term, reversible contraception. 
2.2 Secondary Objectives 
The secondary objectives of this study are to assess: 

The safety, tolerability, bleeding patterns, and continuation rates of LNG20

The occurrence of menses and return to fertility after IUS discontinuation

Plasma pharmacokinetics of levonorgestrel in a subset of approximately 60
subjects with serial sampling over the duration of use

Plasma levonorgestrel levels in a subset of 60 subjects (LNG20 16 – 35 years old
arm only) following IUS removal at 121 months with sampling at various time
points up to 14 days post-IUS removal

Levonorgestrel plasma levels will be obtained for all subjects at each study visit
beginning with Month 36 until  Protocol Version 9 when thereafter,
levonorgestrel plasma levels will be obtained in all subjects at discontinuation and
also annually in all women enrolled prior to 31May2011.

Analysis of  an appropriate sampling of IUSs that are removed and, when
available, expelled during the study
Retrieved from the Medicines360 Veeva EDMS on 27 Sep 2023 by 


Medicines360 
Statistical Analysis Plan 
M360-L102 
02 October 2017 
Page 9 of 38 

The safety and tolerability of LNG20 in a small cohort of women between ages 36
and 45 years up to 8 years of use

Endometrial thickness in a subset of 60 LNG20 16-35 year old subjects at 1 year,
5 years and 10 years
3.
STUDY DESIGN AND PLAN
This is a Phase 3, open-label, multicenter evaluation of the efficacy of a levonorgestrel-
releasing intrauterine system (LNG20).  The original study design included a comparator 
group of a marketed levonorgestrel-releasing intrauterine system (Mirena) to provide 
comparative safety and tolerability data for European regulatory approval.  The study 
design changed such that the Mirena group would no longer be needed for comparison; 
hence the recruitment of the Mirena group was terminated with 159 subjects enrolled.  
The data from these subjects will be used as an informative comparator only in summary 
demographic, medical history, adverse event incidence, vital signs, and laboratory results 
tables given the final Mirena group sample size.   
The goals of the study include provision of information to understand efficacy and safety 
within the widest range of possible users of the LNG20.  Typically, intrauterine 
contraceptive studies only include women 18-35 years of age for efficacy and safety, and 
place limits on parity and larger body size.  Women outside of these characteristics also 
desire an effective intrauterine contraceptive.  Accordingly, this study will include 
women who are both nulliparous and parous as well as women less than 18 years of age 
in the primary efficacy and safety analyses.  Additionally, we will provide safety 
information on women greater than 35 years of age.  Also, this study does not restrict 
enrollment based on weight or BMI. 
Eligible subjects for the efficacy evaluation of LNG20 will include a minimum of 
approximately 1600 subjects 16-35 years of age using LNG20.  In the original protocol, 
approximately 650 LNG20 and 160 Mirena subjects were randomized at a 4:1 ratio of 
LNG20 to Mirena.  In the amended single-arm protocol currently in force, the remaining 
approximately 950 subjects will be assigned to LNG20 only.  The 1600 LNG20 subject 
total represents the combined LNG20 exposure in women aged 16-35 under protocol 
versions 1.0 through 4.0 using the original inserter and protocol versions 5.0 and later 
utilizing the redesigned LNG20 inserter.  Subjects in the Treatment PK substudy 
(approximately 60) will be assigned by the IVRS separately from the remainder of study 
subjects based on BMI.  An additional 150 eligible females 36-45 years of age will 
receive LNG20 as part of a non-randomized cohort to provide additional safety and 
tolerability information, since IUSs are used with relative frequency by women over the 
age of 35.  
Retrieved from the Medicines360 Veeva EDMS on 27 Sep 2023 by 


Medicines360 
Statistical Analysis Plan 
M360-L102 
02 October 2017 
Page 10 of 38 
Subjects who discontinue treatment for any reason will not be replaced. 
After consent is obtained, screening procedures will be performed and eligible subjects 
enrolled into the trial via an Interactive Voice Response System (IVRS).  Enrollment and 
IUS insertion may occur on the same day as the screening procedures.  The assigned IUS 
will be inserted by a study Investigator using standardized procedures specific to each 
system. 
LNG20 subjects will be evaluated during study treatment use for up to 85 months 
(Mirena subjects for up to 60 months).  Study assessments will be performed at a clinic 
visit at Screening/Enrollment and Months 1, 3, 6, 12, 18, 24, 30, 36, 42, 48, 54, 60, 66, 
72, 78, 84, 90, 96, 102, 108, 114, 120 and 121 (Mirena subjects only through Month 60 
and LNG20 36-45 years old subjects only through Month 96).  Telephone assessments 
will occur at 3 month intervals between scheduled study visits, starting at Month 9.  The 
IUS will be removed when requested by the subject, when clinically indicated, when 
requested by investigator or sponsor, or at the end of 121 months of use (60 months for 
Mirena subjects and 96 months for LNG20 36-45 years old group).   
All subjects will have a follow-up safety visit one month after discontinuing the study 
treatment.  Additional follow-up will be conducted for subjects who: 

Have an ongoing IUS or IUS procedure-related adverse event

Choose a non-hormonal contraceptive method or who indicate that they will
attempt to become pregnant, as follows:
o
Those women who elect to start a non-hormonal contraceptive method or
no contraception (including those desiring pregnancy) will be followed for
return of menses or until diagnosis of secondary amenorrhea is determined
o
Those women who desire pregnancy will be followed for up to 12 months
to document return to fertility
Pregnancies that occur during study treatment or after IUS discontinuation through the 
30-Day Safety Follow-up Visit will be identified through subject query and urine and
serum pregnancy testing.  The date of conception will be confirmed by ultrasound
examination for pregnancies that occur during study participation.  All pregnancies with a
date of conception “on treatment” (while the IUS remains in place or up to and including
7 days following IUS discontinuation) will be followed to completion and the outcome
recorded.
Retrieved from the Medicines360 Veeva EDMS on 27 Sep 2023 by 


Medicines360 
Statistical Analysis Plan 
M360-L102 
02 October 2017 
Page 11 of 38 
Routine safety monitoring (including clinically indicated physical exams, adverse event 
assessments, and vital signs) will be conducted for all subjects.  An Independent Data 
Monitoring Committee (IDMC) will monitor subject safety throughout study conduct, 
and will be sent reports of all unexpected related serious adverse events (SAEs) that may 
occur during the study.  The IDMC will review all safety data and pregnancy rates, and 
make recommendations regarding study conduct. 
Subjects will receive detailed instructions on how to record vaginal bleeding, 
dysmenorrhea, and other contraceptive use on a daily diary during the first 24 months of 
study participation.  Thereafter, only other contraceptive use will continue to be recorded 
daily on a diary for the remainder of study treatment in addition to the information 
collected at each study visit.  After 24 months, bleeding and dysmenorrhea information 
will be obtained for the remainder of study treatment via interviews by study staff during 
each study follow-up visit and contact (every 3 months) during treatment.   
In addition, levonorgestrel plasma levels will be obtained for all subjects every 6 months 
and at IUS discontinuation beginning with Month 36 until  Protocol Version 9 when 
thereafter, levonorgestrel plasma levels will be obtained in all subjects at IUS 
discontinuation and also annually in all women enrolled prior to 31May2011. 
The Sponsor intends to retain all IUSs that are removed or expelled (when possible) and 
analyze an appropriate sample of these systems.  
The following substudies will be performed at selected sites: 

Levonorgestrel PK data will be obtained in a subset of approximately 60 subjects
(20 non-obese LNG20 subjects, 20 non-obese Mirena subjects and 20 obese
LNG20 subjects).  LNG plasma samples will be obtained at Enrollment (pre-IUS
insertion), Weeks 1 and 2, and Months 1, 3, 6, 9, 12, 18, 24, 30 or Early
Discontinuation after IUS insertion (includes three extra visits at Weeks 1 and 2,
and Month 9, not included in the main study).  These subjects will be required to
give informed consent for participation in the levonorgestrel PK subset

A subset of 60 subjects assigned to LNG20 and completing 121 months of study
treatment will have levonorgestrel samples obtained at various time points after
IUS removal to characterize the LNG elimination profile.  Each subject in this
subset will be randomized to one time point (one extra visit) post-IUS removal
(24 hours, 48 hours, 7 days or 14 days) such that fifteen subjects are randomized
to each time point
Retrieved from the Medicines360 Veeva EDMS on 27 Sep 2023 by 


Medicines360 
Statistical Analysis Plan 
M360-L102 
02 October 2017 
Page 12 of 38 

A subset of 60 women assigned to LNG20 at selected sites will have transvaginal
ultrasound evaluations at enrollment (pre-IUS insertion), one year, five years and
ten years (pre-IUS removal) to assess changes in endometrial thickness
4.
DETERMINATION OF SAMPLE SIZE
Sample size was determined to achieve an acceptable Pearl Index through a minimum of 
10 years of use.  Eligible subjects 16-35 years of age will include approximately 1,600 
subjects using LNG20 and 160 subjects using Mirena.  In the original study protocol, 
approximately 650 LNG20 and 160 Mirena subjects were randomized in a 4:1 ratio of 
LNG20 to Mirena.  However, under the amended single-arm protocol currently in force 
(version 5.0 or later), the remaining 950 subjects will be assigned to LNG20 only.  
Estimation of the required number of subjects needed to evaluate the contraceptive 
efficacy of LNG20 is based on the Pearl Index, defined as the estimated rate of pregnancy 
per 100 women per year based on thirteen 28-day cycles of exposure per year.  For this 
study, the following assumptions have been made regarding the Pearl Index:  

It is estimated to be less than 0.280

The difference between the point estimate and the upper limit of the 95%
confidence interval of the Pearl Index calculated for each year of use will be no
larger than 1 unit (Benda et al, 2004; Gerlinger et al, 2003)

Early discontinuations due to dropouts, IUS expulsions, pregnancies and other
reasons will not exceed 20% in year 1, 19% per year in year 2, 17% in year 3, and
16% per year in year 4, year 5, year 6, year 7, year 8, year 9 and year 10, and will
result in a cumulative discontinuation over 10 years of 76%

Loss of women-months for use in calculating the Pearl Index will not exceed 0.6
months per subject in year 1 and 0.3 months per year in years 2, 3, 4, 5, 6, 7, 8, 9
and 10
With these assumptions, it is expected that, for the efficacy analysis, 1,600 LNG20 
subjects (16-35 years old) will provide at least 10,000 woman-months (28-day cycles) of 
exposure in the first two years with at least 200 subjects having at least two years of 
LNG20 exposure within that total 28-day cycle calculation.  In addition, the planned 
sample size assumes that at least 375 women will still be on treatment through the end of 
ten years.  For the purposes of calculating the Pearl Index, a minimum of 200 women 
must complete each year of study.   
Retrieved from the Medicines360 Veeva EDMS on 27 Sep 2023 by 


Medicines360 
Statistical Analysis Plan 
M360-L102 
02 October 2017 
Page 13 of 38 
5.
GENERAL ANALYSIS CONSIDERATIONS
5.1 Data Summaries 
Summary tables, figures, and data listings will be used to report the efficacy and safety 
outcomes for this study.    Continuous variables will be summarized with means, standard 
deviations, medians, minimums, and maximums.  Categorical variables will be 
summarized by counts and by percentage of subjects in corresponding categories.  No 
formal statistical testing of any kind will be performed for this study. 
Efficacy summaries consisting of the Pearl Index point estimate and its 95% confidence 
interval will be limited to the LNG20 16-35 year old study population, and the principal 
calculation based on all 28-day cycles of use where no other birth control method was 
reported.  Subgroup assessments of pregnancy outcomes by a priori defined criteria, e.g., 
BMI, will be presented for the LNG20 16-35 year-old and LNG20 36-45 year-old study 
populations.  Safety summaries will include the LNG20 16-35 year-old, LNG20 36-45 
year old, and Mirena study populations.  Depending on the safety endpoint of interest, the 
LNG20 study populations may be presented as a pooled sample of all subjects exposed to 
LNG20. 
Individual subject data obtained from the case report forms (CRFs), pharmacokinetic 
data, and any derived data will be presented by treatment group and subject in data 
listings.  This will include subject-level data listings by site as described 
that include derived data fields (e.g., estimates for missing adverse event onset dates) will 
include the original reported data and the derived value. 
All forms of output described in this plan or any amendment that follows prior to any 
database cut-off for analyses or final database lock are considered a priori considerations.  
Any analyses performed subsequent to database cut-off or final database lock will be 
considered post-hoc and exploratory.  Post-hoc analyses will be identified in the CSR. 
All analyses and tabulations will be performed using SAS Version 9.3 or higher.  
Pharmacokinetic analyses will be performed using Phoenix WinNonlin Version 6.4.  
Tables, figures, and listings will be presented in RTF/DOC (MS Word-readable) format.  
Upon completion, all SAS programs will be validated by an independent programmer.  In 
addition, all program output will undergo a senior level statistical review.  The validation 
process will be used to confirm that statistically valid methods have been implemented 
and that all data manipulations and calculations are accurate.  Checks will be made to 
Retrieved from the Medicines360 Veeva EDMS on 27 Sep 2023 by 


Medicines360 
Statistical Analysis Plan 
M360-L102 
02 October 2017 
Page 14 of 38 
ensure accuracy, consistency with this plan, consistency within tables, and consistency 
between tables and corresponding data listings.  Upon completion of validation and 
quality review procedures, all documentation will be collected and filed by the project 
statistician or designee. 
5.2 Data Handling 
5.2.1 Conventions 
Percentages will be based on available data, and denominators will generally exclude 
missing values.  
The precision of the original measurements will be maintained in summaries and listings, 
when possible.  Generally, means, medians and standard deviations will be presented 
with an increased level of precision as follows: means and medians will be presented to 
one more decimal place than the raw data, and the standard deviations will be presented 
to two more decimal places than the raw data. 
Summaries of continuous variables that have some values recorded using approximate 
values (e.g. < or >) will use imputed values.  The approximate values will be imputed 
using the closest exact value for that measurement.  Listings will present the data in the 
original format. 
For tables where rounding is required, rounding will be done to the nearest round-off 
unit.  For example, if the round-off unit is the ones place (i.e., integers), values >= XX.5 
will be rounded up to XX+1 while values < XX.5 will be rounded down to XX.   
For frequency counts of categorical variables, categories whose counts are zero will be 
displayed for the sake of completeness.  For example, if none of the subjects discontinue 
due to “lost to follow-up,” this reason will be included in the table with a count of 0. 
Categories with zero counts will not have zero percentages displayed.   
5.2.2 Unscheduled Visits 
Unscheduled visits will be used in the determination of baseline value when applicable, 
but will otherwise only be listed in the applicable data listings. 
5.3 Handling of Dropouts or Missing Data 
Unless otherwise specified, missing data will not be imputed. Subjects who drop out will 
not be replaced and all available data will be used. 
Retrieved from the Medicines360 Veeva EDMS on 27 Sep 2023 by 


Medicines360 
Statistical Analysis Plan 
M360-L102 
02 October 2017 
Page 15 of 38 
5.3.1 Diary Data 
Daily diary entries by the subject are made directly onto paper CRFs and are, therefore, 
"self-sourcing" source data.  If a subject does not bring the original (O) diary to the clinic 
visit, then the site will ask the subject to recall the data on a diary copy (C).  The copy 
will be used until the original is returned at a following clinic visit.  During the first 24 
months of the study, the diary data for bleeding, cramping and other contraception use 
will be recorded by the subject on a daily basis.  Beginning after month 24, the subject 
will continue to record other contraception use on a daily diary but bleeding and 
cramping information will be characterized on a bleeding/cramping form completed by 
the site through subject interview approximately every 3 months. 
If the original diary becomes available after the data from the copy have been entered 
into the study data base, the data base will be updated to include the original diary data 
along with the copy.  The data base audit trail will reflect initial data entry from the copy 
followed by subsequent entry of the original.  Diaries returned by the subject that include 
days when no information was obtained have those data records included in the data base.  
However, no such blank records are in the data base for entire diary pages that may have 
not been returned, e.g., the subject may have returned diaries for March and May but 
never returned the April diary.  In these cases, missing data are not part of the data base 
but are accounted for as blank records in the same manner as those which appear, 
essentially at random, within a returned diary.  Since the diary day counting process for 
identification of 28-day cycles when another birth control method use was reported looks 
at each diary date record relative to the IUS insertion date, the presence of missing diary 
records will not affect this calculation.  The extent and magnitude of missing diary 
records will be assessed and presented as part of overall diary results.  
Diary numbers on CRFs will not be used; only the date information on the CRF will be 
used.  If the date recorded does not exist, the data will not be included.  If the subject 
never returns the original copy, the copy will be used for analyses.  Duplicate diary 
records (e.g., an original and a clinic copy) for the same study day can appear in the study 
data base and should be handled as follows: 

If the diaries represent an original diary and a clinic copy diary, the original diary
data will serve as the diary data of record.

If the diaries are submitted as duplicates of the same original or same clinic copy,
the most recently submitted version will be used for analyses.
Bleeding and cramping categories are listed below in order of increasing severity. 

Bleeding: None, Spotting, Light Flow, Normal Flow, Heavy Flow.
Retrieved from the Medicines360 Veeva EDMS on 27 Sep 2023 by 


Medicines360 
Statistical Analysis Plan 
M360-L102 
02 October 2017 
Page 16 of 38 

Cramping: None, Mild, Moderate, Severe.
Note: In an early version of the diary, this information was recorded as None, Spotting, 
or Bleeding.  In the analysis, if the subject did not complete a revised diary, the category 
of “bleeding” will be considered “Normal Flow.” 
5.3.2 Bleeding, Cramping, and Other Contraceptive Use 
For the categories of bleeding, cramping and other contraception use, no imputation of 
data from the diaries will be done for missing data.  For example, a subject with 
completely missing data for a particular diary day will be considered as having no 
reported bleeding, no cramping, no other contraceptive use, etc. for that day.  Missing 
data for, say, bleeding alone will be considered as the subject having no reported bleeding 
for that day. 
5.3.3 Missing Adverse Event Start and Stop Dates 
For adverse events (AE), the following rules for imputing values for missing start dates 
are used: 

If the AE start date field includes a SAS missing value (e.g., .N) or is completely
missing, the start date is set to the IUS insertion attempt date.  This
conservatively assumes that the AE began on the same date when insertion was
first attempted.
If the AE start date field is missing day only, set it equal to the first day of the
recorded month and year.

If the AE start date field is missing day and month only, set it equal to the first
day of January of the recorded year.

Any resultant imputed AE start date that is earlier than the IUS insertion attempt
date is set equal to the IUS insertion attempt date.  This also conservatively
assigns the AE as having occurred on the same date as the IUS insertion attempt.

If the AE stop date is completely missing, the event will be noted as
“Continuing” in the stop date column in the AE listings.

If the AE stop date field is missing day only, set it equal to the 15th day of the
recorded month and year

If the AE stop date field is missing day and month only, set it equal to the 31st
day of December of the recorded year.
Retrieved from the Medicines360 Veeva EDMS on 27 Sep 2023 by 


Medicines360 
Statistical Analysis Plan 
M360-L102 
02 October 2017 
Page 17 of 38 

If the AE stop date field is missing month only, set it equal to December of the
recorded year.

A resultant imputed AE stop date that is earlier than the AE start date is set equal
to the AE start date.  This ensures that that all AEs have a minimum  duration of
one day.
5.3.4 Missing Concomitant Medication Start and Stop Dates 
For concomitant medications (CM), the following rules for imputing values for missing 
start dates are used: 

If the CM start date field includes a SAS missing value or is completely missing,
the start date is set to the IUS insertion attempt date.

If the CM start date field is missing day only, set it equal to the first day of the
recorded month and year.

If the CM start date field is missing day and month only, set it equal to the first
day of January of the recorded year.

If the CM stop date field includes a SAS missing value or is completely missing,
the stop date is set to the last date of known product use.

If the CM stop date field is missing day only, set it equal to the 15th day of the
recorded month and year

If the CM stop date field is missing day and month only, set it equal to the 31st
day of December of the recorded year.

If the CM stop date field is missing month only, set it equal to December of the
recorded year
Any imputed CM stop date that is before the insertion attempt date implies the CM
was a Pre-Trial Medication.  Any medication started on or after the insertion
attempt date or any medication started before insertion but ending on or before the
last known date of product use is a Concomitant Medication.
5.3.5 Missing Dates for Other Events, Including Return to Menses, Return to Fertility, 
Pap Tests, Date of IUS Expulsion/Removal, and Reported Pregnancies 
For missing dates of other events, any date that is completely missing or contains the year 
only will be set to the date of the subject’s last clinic visit. If a month and year are 
recorded but the day is unknown, the day will be set to the first day of the month. If this 
Retrieved from the Medicines360 Veeva EDMS on 27 Sep 2023 by 


Medicines360 
Statistical Analysis Plan 
M360-L102 
02 October 2017 
Page 18 of 38 
results in an imputed date that is earlier than the last clinic visit, the date will be set to the 
date of the last clinic visit. 
5.4 Standard Calculations 
Variables requiring calculation will be derived using the following formulas: 

Study day – For a given date (date) on or after successful IUS insertion (iusindt),
study day is calculated as:
Study day = date – iusindt + 1
For a given date (date) prior to successful IUS insertion (iusindt) or for subjects with
failed insertion, study day is calculated as:
Study day = date – iusindt.
The day of successful IUS insertion is Study Day 1 and the day prior to IUS insertion
is Study Day -1. There is no Study Day 0
Months – A duration expressed in months is calculated as the number of completed 
calendar months plus the proportion of any partial month completed  A month is 
calculated using the following formula: Duration in months = (date2-date1)/30.4 

Years - A duration expressed in years between one date (date1) and another later
date (date2) is calculated using the formula noted below:
Duration in years = (date2-date1)/365.25

Age - Age is calculated as the number of years from the date of birth (DOB) to the
IUS insertion attempt date (iusindt). For displaying a subject’s age, the following
formula is used:
Age (years) = floor (insertion attempt date - birthdate)/365.25

Body Mass Index (BMI) - BMI is calculated using height (in cm) and weight (in kg):
BMI (kg/ m2) = weight (kg) / [[height (cm)/100]2]

Cycles of Use/– Cycles are calculated using the date the IUS was expelled/removed
(from the IUS Discontinuation CRF).  Total use duration  expressed as the number of
28-day cycles is defined as (IUS expulsion/removal date - date of IUS insertion
(iusindt)+1)/28.  If the expulsion/removal date is unknown then:

Subjects who are still on treatment will have their last known date of product
use used in the cycle calculations in lieu of an IUS expulsion/removal date,
derived as follows:  For the evaluation of safety, the last known date of
product use will be the last date of on-study contact with the subject where
she reported that the IUS is still in place or the last date at which a pregnancy
Retrieved from the Medicines360 Veeva EDMS on 27 Sep 2023 by 


Medicines360 
Statistical Analysis Plan 
M360-L102 
02 October 2017 
Page 19 of 38 
test was performed (at study site or outside laboratory with copy of report), 
whichever is later.  For the evaluation of efficacy, the last date at which a 
pregnancy test was performed will be used (at study site or outside 
laboratory with copy of report). 

If, during on-study contact with the subject (e.g., Month 9 Contact, Month
15 Contact, Month 21 Contact), she reports that the IUS is no longer in
place, the date of contact minus 1 day or last date at which a pregnancy test
was performed (at study site or outside laboratory with copy of report),
whichever is later, will be used as the last date associated with IUS use.

Subjects who become pregnant with the IUS still in place will have their
estimated date of conception used as the last IUS use date.

In the cases of subjects who are lost to follow-up or withdraw consent prior
to IUS removal and neither a last contact date nor a last pregnancy test date
is available, the IUS insertion date + 1 day will be used as the last date
associated with IUS use.
Similarly, for subjects who had a successful IUS insertion but who have not yet had any 
post-insertion data (e.g., diaries or post-insertion pregnancy test results) retrieved at the 
site which could be used to directly calculate duration of use, the IUS insertion date +1 
day will be used as the last date of IUS use for the purpose of analysis.  For the summary 
of duration of product use, all subjects with ≥ 1 days of product use, as defined in this 
section, will be included in the calculations.  For the evaluation of adverse events, 
subjects with less than one calculated complete 28-day cycle of use (at least 23 days) will 
be excluded unless such subjects reported an adverse event at any time during the first 28 
days following IUS insertion (see Section 11.2: Adverse Events for more detail).   
5.5 28-Day Cycles of Use Calculation for Efficacy Evaluation 
In addition to the calculation of 28-day cycles based on last date of IUS use as described 
in Section 5.4,  the efficacy evaluation requires the exclusion of cycles from the Pearl 
Index denominator where the use of other birth control methods was reported.   Since this 
information is obtained exclusively from subject daily diaries, 28-day cycles of use need 
to be calculated from the diary data so as to able to determine when the use of other birth 
control methods occurred. 
Using the same algorithm described in Section 5.4, each recorded diary date between the 
IUS insertion date and the last calculated date of product use, inclusively, is compared to 
the IUS insertion date in order to calculate cycle number and day.  Duration of use 
expressed as the number of 28-day cycles is then calculated as the maximum duration 
Retrieved from the Medicines360 Veeva EDMS on 27 Sep 2023 by 


Medicines360 
Statistical Analysis Plan 
M360-L102 
02 October 2017 
Page 20 of 38 
(ceiling value) between the IUS insertion date and last recorded diary date. The number 
of cycles where other birth control methods were used can be calculated directly since 
each recorded diary record is associated with a cycle number and day. 
If the last cycle obtained using either the method described in Section 5.4 or the diary-
based method described here has fewer than 23 days, that cycle is considered incomplete 
and is excluded from the counting process of the number of complete 28-day cycles (see 
Section 9.2: Primary Efficacy Variable for additional discussion).  In addition, if the 
cycle counts obtained using the method described in Section 5.4 and this section result in 
different estimates for the number of completed cycles (usually because a subject has 
stopped completing the diary short of her last site visit or pregnancy test), the smaller of 
the two calculations will be used.  This is a conservative approach that preserves the 
integrity of the available data as the basis of cycle derivation. 
5.6 Multiple Comparison/Multiplicity 
Since no formal statistical tests are planned for this study, there are no provisions for 
multiple comparisons or multiplicity adjustment of study endpoints.  The Pearl Index 
point estimate calculations for each of Years 1 through 10 will include 95% confidence 
intervals that assume an unadjusted two-sided α=0.05.  This is consistent with the manner 
in which the Pearl Index is derived in contraceptive efficacy studies.  That is, the 95% 
confidence interval calculation is used as a tool in determining whether the extent of 
exposure in a given study is adequate to support the precision of the reported Pearl Index 
point estimate. Note that the Pearl Index will be calculated both on the cumulative year-
by-year data and for each year (Years 1 through 10) non-cumulatively. 
5.7 Interim Analysis and Data Monitoring 
 5.6.1 Interim Analyses 
Interim analyses will not be conducted for this study.  Sequential supplements to the 
NDA are planned on a rolling basis beginning after the initial filing and are not 
considered interim analyses.   
 5.6.2 Data Monitoring Committee 
An Independent Data Monitoring Committee (IDMC) will monitor subject safety 
throughout study conduct, and will be sent reports of all unexpected related serious 
adverse events (SAEs) that may occur during the study.  The IDMC will review all safety 
data and pregnancy rates, and make recommendations regarding study conduct.  
Meetings will occur approximately every six months. 
Retrieved from the Medicines360 Veeva EDMS on 27 Sep 2023 by 


Medicines360 
Statistical Analysis Plan 
M360-L102 
02 October 2017 
Page 21 of 38 
5.8 Multicenter Studies 
Given that the principal efficacy measure, the Pearl Index, is computed across the 
combined data across all participating sites, no by-site evaluation or statistical adjustment 
for site-to-site variation is planned.  Summary presentations by site may be considered for 
specific descriptive variables, e.g., demographic factors, on  a by-site basis if warranted.  
5.9 Subgroup Analyses 
Relevant efficacy and safety summaries will be repeated for the following subgroups, 
using the primary analysis population: 

Age (completed years): < 18, 18 – 30, 31 – 35

Parity: nulliparous vs.  parous

Race: White  vs. Non-white

Body Mass Index (BMI; kg/m2 round to one decimal place): < 24.9, 25.0 – 29.9,
30.0 – 39.9, ≥ 40

LNG20 inserter: original  (protocol versions 1.0-4.0) vs. redesigned (protocol
versions 5.0, 6.0, 7.0, 8.0, 9.0)
The Pearl Index will not be calculated within each of these subgroups; instead, crude 
efficacy rates will be presented.  The Pearl Index calculation becomes less meaningful 
and difficult to interpret in this situation as the number of available cycles for the 
exposure denominator necessarily and rapidly diminishes.  Also, because these calculated 
rates rely on the number of subjects as the denominator,  individual 28-day cycles of use 
where other contraceptive methods have been reported will not be considered for 
exclusion. 
6.
ANALYSIS POPULATIONS
The Safety population will include all subjects enrolled who underwent the IUS insertion 
procedure, regardless of age and outcome.  Treatment assignment will be based on the 
treatment actually received. 
The following subject populations will be used for efficacy analyses:  

Modified Intent-to-Treat (MITT) population will include all subjects between 16
and 35 years of age at study entry for whom the assigned IUS is successfully
Retrieved from the Medicines360 Veeva EDMS on 27 Sep 2023 by 


Medicines360 
Statistical Analysis Plan 
M360-L102 
02 October 2017 
Page 22 of 38 
placed in the uterus and for whom there is at least one assessment of pregnancy 
status after inserting the IUS.   

Per-Protocol (PP) population will include subjects in the MITT population with
no major protocol deviations (to be identified prior to database cut-off).
The Treatment Pharmacokinetics (PK) population will include all subjects enrolled in the 
substudy and have at least one post-insertion PK assessment and no major protocol 
deviations. 
The Elimination PK population will include all subjects enrolled in the substudy (who 
will be randomized to one time point post-IUS removal) and whose post-IUS removal PK 
assessment is not missing.  The elimination PK sampling will only be obtained at the full 
intended duration of use IUS removal visit (i.e. Month 121). 
The Endometrial Thickness (ET) population will include all subjects enrolled in the ET 
substudy and have at least one post-insertion ET measurement.  The final endometrial 
thickness measurements will be obtained at baseline, Month 12, Month 60 and after the 
full intended duration of use (i.e. 10 years). 
7.
STUDY POPULATION SUMMARIES
7.1 Subject Disposition 
Subject disposition information will be summarized for all subjects, by treatment group 
and by site.  Summaries will include: the number of enrolled subjects, the number of 
subjects with successful IUS insertion (first and second attempt), the number of subjects 
who discontinued after failed insertion, the number of subjects in each analysis 
population, the number of subjects completing each visit and the study, and the primary 
reason for discontinuation. 
7.2 Protocol Deviations 
Major protocol deviations that could potentially affect the primary protocol outcome 
(efficacy) will be identified prior to database cut-off.   
7.3 Demographic and Baseline Characteristics 
Demographic variables include: age, sex, ethnicity, and race.  Other baseline 
characteristics include: marital status, partner status, height, weight, BMI, medical 
history, gynecological history, menstrual history, and pregnancy history.  General 
Retrieved from the Medicines360 Veeva EDMS on 27 Sep 2023 by 


Medicines360 
Statistical Analysis Plan 
M360-L102 
02 October 2017 
Page 23 of 38 
menstrual history, menstrual history on hormones in the last three months and without 
hormones in the last three months will be summarized. 
Demographic and baseline characteristics will be summarized for the Safety, MITT, 
Treatment PK, Elimination PK, and ET populations.  If the MITT and PP populations are 
not equivalent, the demographic and baseline characteristics will be summarized for the 
PP population as well.  
8.
TREATMENT AND MEDICATION
8.1 Pre-trial and Concomitant Medications 
Verbatim terms on eCRFs will be mapped to the narrowest 
Anatomical/Therapeutic/Chemical (ATC) class possible and generic drug names using 
the World Health Organization (WHO) Drug Dictionary Enhanced (DDE).  For example, 
if the 4th level is not available, then the 3rd level (pharmacological subgroup) will be 
provided. 
Concomitant medications include any medication or health product (any prescription 
medications or over-the-counter preparations) taken during the active study treatment 
period.  Pre-trial medications include any medications taken within seven days (30 days 
for anticoagulants) of enrollment.  Concomitant medications will be summarized for each 
treatment group by WHO ATC class and generic drug name.  These summaries will 
present the number and percentage of subjects using each medication.  Subjects may have 
more than one medication per ATC class and Generic Drug Name.  At each level of 
subject summarization, a subject is counted once if she reported one or more medications 
at that level.  Each summary will be ordered by descending order of incidence of ATC 
class and generic drug name within each ATC class. 
8.2 Extent of Exposure 
The number of women-months (28-day cycles) and women-years of exposure will be 
summarized by treatment group.  Exposure to study IUS will be summarized using 
treatment duration in months both by treatment group and combined across LNG20 
treatment groups (16-35 y.o. and 36-45 y.o).   
9.
EFFICACY ANALYSES
The primary efficacy analysis will be based on the MITT population.  Additional 
supportive efficacy analyses will be performed using the PP population, unless the 
populations are equivalent, as well as the Safety Population.  
Retrieved from the Medicines360 Veeva EDMS on 27 Sep 2023 by 


Medicines360 
Statistical Analysis Plan 
M360-L102 
02 October 2017 
Page 24 of 38 
9.1  Pregnancy on Study 
For all pregnancy analyses, pregnancy is defined as occurring when a positive urine or 
blood pregnancy test is reported.  Confirmation of pregnancy should be attempted by the 
study site and may include: 

urine pregnancy test at the study site

serum quantitative hCG (at study site or report)

ultrasound examination confirming a pregnancy (at study site or report)

a surgical procedure for treatment of an extrauterine pregnancy or intrauterine
pregnancy (report)
A pregnancy is considered to have occurred "on treatment" if a test or examination 
confirms a pregnancy and with a date of conception while the IUS is being used as a 
method of contraception by the subject up to and including 7 days after IUS 
discontinuation.  Pregnancies solely reported by the subject that cannot be verified by any 
means of examination or follow-up reporting will be evaluated for determination of 
whether they should be classified as "on treatment" or "not on treatment" for the MITT 
and PP efficacy evaluations. All reported pregnancies, even if not confirmed by the site, 
will have a Pregnancy Narrative completed by the study investigator. 
9.2 Primary Efficacy Variable 
The primary efficacy variable is the Pearl Index, an estimation of the number of 
unintended pregnancies per 100 women-years of exposure.  The Pearl Index is calculated 
as the number of "on treatment" pregnancies in the study divided by the total number of 
complete 28-day cycles of use (as defined in Section 5.5) in the study across all 
participating subjects, that result multiplied by 1300 (13 cycles x 100 years).  In the case 
of subjects who are still on study at the time of a Pearl Index calculation, the last known 
date of product use (defined in Section 5.4) will be used in place of the IUS 
discontinuation date.  A “last cycle” computed using this algorithm will be considered 
complete if it is at least 23 days in length.  In addition, subjects who become pregnant 
will have that last cycle counted as completed for the Pearl Index calculation, regardless 
of length.   
For the primary Pearl Index outcome using exposure information through Year 5, the 
MITT population will be used as the basis of exposure and all 28-day cycles where use of 
another birth control method was reported in the daily diary will be excluded from the 
total cycle count denominator.  Diary days when no information regarding the use other 
birth control methods is reported will be considered days when no other birth control 
method use took place. The Pearl Index will be calculated using both the cumulative data 
Retrieved from the Medicines360 Veeva EDMS on 27 Sep 2023 by 


Medicines360 
Statistical Analysis Plan 
M360-L102 
02 October 2017 
Page 25 of 38 
through Year 10 and as individual, non-cumulative year-by-year estimates (see Section 
10.1). 
For the definitive assessment of contraceptive efficacy, the Pearl Index and its 95% 
confidence interval will be considered the primary result for inferences. 
9.3 Secondary Efficacy Variables 
In addition to the primary Pearl Index efficacy analysis in the MITT population, the Pearl 
Index will also be calculated as secondary efficacy variables as follows:  

MITT with no cycle exclusions
This calculation will include all “on treatment” pregnancies in the numerator and
all cycles of use in the denominator.  No cycles will be excluded from the
denominator.

The PP study population: The MITT with no cycle exclusions  but excluding
those subjects with major protocol deviations.  Note that use of other birth control
methods, by itself, does not constitute a subject being excluded from the PP
population.

LNG20 subjects 36-45 years old, excluding all 28-day cycles where use of
another birth control method was reported in the daily diary.  Interpretation of the
Pearl Index estimate for this subgroup will require caution since the available
number of subjects and 28-day cycles of product use will be small and limiting.

Safety Population: LNG20 subjects 16-45 years old, excluding all 28-day cycles
where use of another birth control method was reported in the daily diary

Sub-group analysis by parity, BMI and race

Ectopic pregnancies only
"On treatment" pregnancy rate and its associated 95% confidence interval will also be 
estimated using life table methods with year of use serving as the principal life-table 
classification.  
Life Table analysis will be conducted on the following populations: 

MITT with cycle exclusions

MITT with no cycle exclusions

PP

LNG20 subjects 36-45 years old with cycle exclusions
Retrieved from the Medicines360 Veeva EDMS on 27 Sep 2023 by 


Medicines360 
Statistical Analysis Plan 
M360-L102 
02 October 2017 
Page 26 of 38 

LNG20 subjects 36-45 years old with no cycle exclusions

Safety Population: LNG20 subjects 16-45 years old

Sub-group analysis by parity, BMI and race

Ectopic pregnancies only
The life table evaluation with cycle exclusions adjusts for cycles where another birth 
control method was used. Specifically, it will incorporate the calculation of an 
"absolute time"-based duration of use that adjusts for cycles where use of another 
BCM was reported. Duration of use would be based on the total number of 28-day 
cycles of exposure adjusted downward to account for those cycles where other BCM 
use was reported, the result converted into years of product use by multiplying by 28 
(number of days per 28-day cycle) and then dividing by 364 (number of days in a 13 
28-cycle year).
9.4 Secondary Efficacy Evaluations for Pre-Specified Subgroups 
Calculation of crude pregnancy rates, life table evaluation of efficacy and summary of 
pregnancy outcomes will be performed within each of the subject subgroups defined in 
Section 5.9 of this SAP.  The life table evaluation will include both the unadjusted and 
cycle-adjusted for other birth control method use algorithms described in Section 9.3.   
Pearl Index calculations will not be performed within each of these subgroups, per the 
reasons given in Section 5.9, e.g., the lack of meaningfulness of the Pearl Index when the 
number of cycles of exposure is reduced as a result of the subgroup breakdown.  
10. METHODS OF EFFICACY ANALYSIS
10.1 Primary Efficacy Analyses 
The primary efficacy endpoint is the Pearl Index for LNG20 women 16-35 years old.  
The Pearl Index and associated 95% confidence interval (CI) will be presented using the 
MITT population to establish efficacy for two years of use.  Acceptable precision of the 
Pearl Index is expected to establish efficacy of LNG20 where acceptable precision is 
typically defined as the upper bound of the 95% CI being no more than 1 unit greater 
than the point estimate of the Pearl Index. 
Since the number of cycles of exposure during the first year is the lowest, this precision 
of the Pearl Index may not be fully observable if limited to the first year alone. Therefore, 
while a Pearl Index estimate at year 1 and its 95% confidence interval will be obtained 
using the available exposure information for year 1 alone, the upper bound of the 
Retrieved from the Medicines360 Veeva EDMS on 27 Sep 2023 by 


Medicines360 
Statistical Analysis Plan 
M360-L102 
02 October 2017 
Page 27 of 38 
confidence interval associated with that estimate may be wider than the “no greater than 1 
unit” criterion for years 2, 3, 4, 5, 6, 7, 8, 9 and 10.  The Pearl Index for primary efficacy 
will therefore be calculated as cumulative and also non-cumulative year-by-year. 
10.2 Secondary Efficacy Analyses 
10.2.1 Pearl Indices 
The cumulative Pearl Index analyses described above for the primary efficacy analysis 
will also be performed every year after Year 2.  The analysis at Years 3, 4, 5, 6, 7, 8, 9 
and 10 will only be completed if the efficacy of LNG20 for the preceding years of use 
meets acceptable precision, where acceptable precision is defined as the upper bound of 
the 95% confidence interval being no more than 1 unit greater than the point estimate of 
the Pearl Index.  Pearl Index calculations will be done when a minimum of 200 women 
complete each subsequent year of the study. 
10.2.2 Pregnancy Rates 
Life table methods will be used to estimate the overall pregnancy rate for each year and 
the cumulative pregnancy rate after each year.  Both uterine and ectopic pregnancies will 
be included.  Pregnancy dating and confirmation will be determined by medical 
assessments, including ultrasound examination.  Confirmed pregnancy is the failure 
outcome and the corresponding time to pregnancy is the failure time.  Time to pregnancy 
will be calculated as the date of conception minus the date of IUS insertion plus one 
(partial or completely missing conception dates handled per Section 5.3.5).  Subjects who 
do not get pregnant will be censored at the last pregnancy assessment and failure time 
will be calculated as the date of the last pregnancy assessment minus the date of IUS 
insertion plus one.  
Additionally, an overall Ectopic Pregnancy (EP) rate will be calculated as EP Rate per 
100 Woman Years (WY) for the duration of use: 
Number of EPs/WYs (number of 28-day cycles) = x/100 WY.   The number of 28-day 
cycles per subject is not to exceed the duration of use being evaluated. 
10.3 Pharmacokinetic Analyses 
10.3.1 Plasma Concentrations during IUS Use 
Plasma concentrations before insertion of the IUS, and then at Days 7 and 14, and 
Months 1, 3, 6, 9, 12 18, 24, 30 during IUS use will be analyzed using the Treatment PK 
Retrieved from the Medicines360 Veeva EDMS on 27 Sep 2023 by 


Medicines360 
Statistical Analysis Plan 
M360-L102 
02 October 2017 
Page 28 of 38 
population.  Summaries will be presented for non-obese LNG20, non-obese Mirena, 
obese LNG20, and total LNG20 subjects.  Data listings will be provided for all subjects 
in the PK population. 
The plasma concentrations will be summarized at each time point using descriptive 
statistics, including geometric means, in tabular format.  Plasma concentrations over time 
will be plotted by treatment group.  Plasma concentrations reported as below the level of 
quantification (BLQ) will be set to zero for the purposes of summarizing and plotting 
concentrations. 
10.3.2 Pharmacokinetic Parameters during IUS Use 
For each subject, PK parameters will be determined using a non-compartmental 
approach.  The following PK parameters will be calculated: Cssave (pg/mL) and AUC0-last 
(day * pg/mL).  For the purpose of the non-compartmental PK analysis, all plasma 
concentrations below the limit of quantification (BLQ) occurring after the first 
measurable plasma concentration will be set to zero).   
PK parameters will be summarized at each time point using descriptive statistics, 
including geometric means.   
Additionally, analyses of the effects of race and body weight on LNG exposure and 
exposure-response data for the secondary endpoints of return to menses (RTM), return to 
fertility (RTF) and endometrial thickness (ET) will be performed. 
10.3.3 Elimination PK 
PK data will be summarized at each time point using descriptive statistics, including 
geometric means.  Plasma concentrations over the first 14 days following LNG20 
removal after 121 months of use will be summarized using the Elimination PK 
population.  For the purpose of this analysis, all plasma concentrations below the limit of 
quantification occurring after the first measurable plasma concentration will be set to 
zero.   
A population PK type analysis will be also performed. 
10.4 IUS Analysis Post-Removal 
Analysis of an appropriate sampling of IUSs for residual LNG content that are removed 
or expelled during the study will be summarized and plotted as a function of time of 
removal/expulsion.   
Retrieved from the Medicines360 Veeva EDMS on 27 Sep 2023 by 


Medicines360 
Statistical Analysis Plan 
M360-L102 
02 October 2017 
Page 29 of 38 
11. SAFETY ANALYSIS
All safety analyses will be based on the Safety population.   
11.1 Pregnancy Outcomes 
Pregnancy outcomes will be summarized by treatment group. 
11.2 Adverse Events 
Menstrual bleeding and cramping/pain for the first 24 months are recorded in a daily 
subject diary and not on the Adverse Events CRF (unless the event is an SAE, results in 
IUS removal or is not related to the IUS or menstrual condition).  The subject daily diary 
has been designed to collect IUS and menstrual bleeding and cramping AEs following 
insertion of the study IUS.  Menstrual bleeding or cramping/pain would only be entered 
onto the general AE CRF if:  

Bleeding or cramping/pain meet serious criteria; an SAE report would also have
to be submitted (this exception is due to data system requirements)

Bleeding or cramping/pain result in the IUS being removed (this exception is
due to data system requirements)

Bleeding or cramping/pain is not related to the IUS or a menstrual condition.
After 24 months, menstrual bleeding and cramping/pain are recorded on the Adverse 
Events CRF.  Analyses of cramping/pain and bleeding are described below in section 
11.6 . 
All adverse event summaries will be restricted to treatment-emergent adverse events 
(TEAE), defined as AEs occurring during or after attempted IUS insertion and those pre-
attempted IUS insertion existing medical conditions that worsened during the study up to 
the subject's last known IUS date of use or, for subjects who have discontinued, through 
30 days after the subject's last known IUS date of use. If an AE cannot be determined as 
treatment-emergent, it will be counted as such. 
Verbatim terms on case report forms will be mapped to preferred terms and system organ 
classes using the Medical Dictionary for Regulatory Activities (MedDRA) dictionary.  
Each adverse event summary will be displayed by treatment group.  Summaries that are 
displayed by system organ class and preferred terms will be ordered by descending order 
of incidence of system organ class and preferred term within each system organ class.  
Summaries of the following types will be presented: 
Retrieved from the Medicines360 Veeva EDMS on 27 Sep 2023 by 


Medicines360 
Statistical Analysis Plan 
M360-L102 
02 October 2017 
Page 30 of 38 

Overall subject summary of AEs, SAEs, and deaths

Subject incidence of TEAEs and total number of unique TEAEs by MedDRA
system organ class and preferred term.

Subject incidence of TEAEs by MedDRA system organ class, preferred term, and
highest severity.  At each level of subject summarization a subject is classified
according to the highest severity if the subject reported one or more events.  AEs
with missing severity will be considered severe for this summary

Subject incidence of TEAEs by MedDRA system organ class, preferred term, and
closest relationship to IUS (Related/Not Related).  At each level of subject
summarization a subject is classified according to the closest relationship if the
subject reported one or more events.  Related will be defined as “Related”,
“Probably Related”, or missing.  Not related will be defined as “Unlikely Related”
or “Not Related”

Subject incidence of TEAEs by MedDRA system organ class, preferred term, and
closest relationship to IUS Procedure (Related/Not Related).  At each level of
subject summarization a subject is classified according to the closest relationship
if the subject reported one or more events.  Related will be defined as “Related”,
“Probably Related”, or missing.  Not related will be defined as “Unlikely Related”
or “Not Related”

Subject incidence of serious TEAEs and total number of unique serious TEAEs
by MedDRA system organ class and preferred term
Incidence rates will include in the denominator all subjects in the Safety Population. 
Missing Severity or Relationship 
Missing severity or relationship to study drug will prompt queries to be sent to the 
investigators to provide the information.  If after query resolution, the information 
remains missing, the following conventions will be used in summary tables. 

An event with missing severity will be considered Severe.

An event with missing relationship will be considered related to study drug.
11.3 Insertion and Removal Related Bleeding and Cramping/Pain 
IUS insertion and removal bleeding and cramping/pain related to IUS insertion and 
removal will be summarized by treatment group.  IUS insertion related bleeding and 
Retrieved from the Medicines360 Veeva EDMS on 27 Sep 2023 by 


Medicines360 
Statistical Analysis Plan 
M360-L102 
02 October 2017 
Page 31 of 38 
cramping/pain are recorded on the IUS Insertion Questionnaire.  IUS removal related 
bleeding and cramping/pain are recorded on the IUS Removal Questionnaire. 
Summaries of the following will be presented: 

Bleeding (none, spotting, light bleeding, moderate bleeding, heavy bleeding)

Cramping/pain  (none, mild, moderate, severe)
11.4 Menstrual Related Cramping/Pain 
11.4.1 Up to Month 24 
For the first 24 months of the study.  A subject will be defined as having menstrual 
cramping/pain (dysmenorrhea) TEAE if: 

The subject diary question, “Check box if cramping today is worse than when not
using hormones” is marked
AND

Baseline cramping/pain or dysmenorrhea is the same or worsens from what is
indicated on the Menstrual History CRF based on menstrual characteristics when
not using hormonal contraception.
If cramping/pain (dysmenorrhea) TEAE is recorded on the Adverse Event CRF and not 
on the subject diary due to the event being an SAE, results in IUS removal or is not 
related to the IUS or menstrual condition, the subject will be counted as having a 
cramping/pain (dysmenorrhea) TEAE.  Subject incidence of cramping/pain or 
dysmenorrhea TEAEs will be described within the overall adverse event incidence 
summary. 
11.4.2 After Month 24 
For Months 25 through 121, cramping/pain (dysmenorrhea) TEAEs will be recorded 
only in the Adverse Event CRF and not determined based on daily subject diary 
responses.  During these months there will be no subject diary for menstrual changes and 
instead a periodic (every 3 months) form characterizing their cramping and 
dysmenorrhea will be used.  Self-reported cramping and dysmenorrhea TEAEs will be 
recorded on the Adverse Event CRF. 
Retrieved from the Medicines360 Veeva EDMS on 27 Sep 2023 by 


Medicines360 
Statistical Analysis Plan 
M360-L102 
02 October 2017 
Page 32 of 38 
11.5 Menstrual Related Bleeding 
11.5.1 Up to Month 24 
For the first 24 months of the study a subject will be defined as having a menstrual 
Bleeding TEAE if: 

The subject diary question, “Check box if bleeding today is heavier than when not
using hormones” is marked
AND

Baseline bleeding that is the same or worsens from what is indicated on the
Menstrual History CRF based on menstrual characteristics when not using
hormonal contraception.
If  a bleeding TEAE is recorded on the Adverse Event CRF and not on the subject diary 
due to the event being an SAE, results in IUS removal or is not related to the IUS or 
menstrual condition, the subject will be counted as having a bleeding TEAE.  Subject 
incidence of bleeding TEAEs will be described within the overall adverse event incidence 
summary. 
11.5.2 After Month 24 
For Months 25 through 121, bleeding TEAEs will be recorded only in the Adverse Event 
CRF and not determined based on daily subject diary responses.  During these months 
there will be no subject diary for menstrual changes and instead a periodic (every 3 
months) form characterizing their bleeding will be used.  Self-reported bleeding TEAEs 
will be recorded on the Adverse Event CRF. 
11.6 Diary Reported Bleeding and Cramping/Pain Analysis 
11.6.1 Months 1-24 
For each 28-day cycle and each 84 and 90 day interval post-insertion, the incidence of 
on-treatment cramping/pain (none, mild, moderate, severe) and bleeding (none, spotting, 
light flow, medium flow, heavy flow) will be calculated based on diary entries and 
presented by treatment group.  Summaries of the following types will be presented: 

Incidence of cramping/pain by 28-day cycle and 84 and 90 day intervals post-
insertion (none vs. ≥1 day; 1-3, 4-7, >7, and >20 days)
Retrieved from the Medicines360 Veeva EDMS on 27 Sep 2023 by 


Medicines360 
Statistical Analysis Plan 
M360-L102 
02 October 2017 
Page 33 of 38 

Incidence by of bleeding by 28-day cycle and 84 and 90 day intervals post-
insertion (none vs. spotting vs. bleeding; none vs. ≥1 day; 1-3, 4-7, >7, and >20
days; no bleeding vs. any bleeding)

Incidence of cramping/pain by highest severity or bleeding by greatest intensity
by cycle and 84 and 90 day intervals post-insertion.  At each level of subject
summarization a subject is classified according to the highest severity or intensity
if the subject reported one or more events.
Descriptive continuous-based statistics (mean, standard deviation, median, minimum, 
maximum) will be used to summarize the number of days of reported cramping and 
bleeding and/or spotting during each 28-day cycle and each 84 and 90-day interval.  The 
number of spotting days and the number of bleeding days (light flow, moderate flow, 
heavy flow combined and each category separately) will also be summarized using this 
approach.  For cramping/pain, this will also be presented within each severity rating, i.e., 
the total number of reported days will be broken down into the number of days of mild, 
moderate, and severe cramping/pain.  
11.6.2 After Month 24 
The incidence of reported cramping every three months after Month 24 will be reported 
using the categories which appear in parentheses below: 
Over the last 3 months has the subject had any menstrual cramping/pain? (Yes/No)
Did the cramping/pain occur mainly when the subject was having any bleeding or
spotting? (Yes/No)
The worst cramping/pain experienced during these months (mild, moderate, severe)
The incidence of bleeding and/or spotting will be presented in a similar fashion based on 
the following questions and categories of response: 
Over the last 3 months has the subject had any menstrual bleeding/spotting?
What was the main pattern of bleeding/spotting the subject experienced for these
months? (Just Spotting, Irregular Bleeding, Regular Bleeding [periods])
The heaviest bleeding experienced for these months (Spotting,
Light Flow, Normal Flow, Heavy Flow)
Retrieved from the Medicines360 Veeva EDMS on 27 Sep 2023 by 


Medicines360 
Statistical Analysis Plan 
M360-L102 
02 October 2017 
Page 34 of 38 
11.7 Site Diaries 
A Site Diary was originally implemented to characterize subject bleeding and cramping 
after Month 24.  The Site Diary had identical bleeding and cramping questions as the 
Subject Diary for Months 1-24.  The Site Diary was replaced with the 
Bleeding/Cramping Form.  Those subjects for which the Site Diary was completed before 
the initiation of the Bleeding/Cramping Form will have similar analysis performed as for 
Months 1-24 for bleeding and cramping pain as outlined in section 11.6.1.    
11.8 Insertion 
All insertion analyses will be presented separately by inserter type, SHI-001 new inserter 
and original inserter, and combined data for both inserters. 
The number and percentage of subjects with a successful insertion and where rigid 
cervical dilation or local anesthesia was used will be presented by treatment group.  The 
distribution of easy, neutral, or difficult insertions will be summarized by treatment 
group.  The summaries will be presented by insertion attempt. 
Summaries will also be presented by inserter type for other inserter-related outcomes, 
such as the number and percentage of subjects where insertion failure occurred, difficulty 
of insertion, use of cervical dilation, perforation, expulsion, and insertion-related bleeding 
and cramping. 
Some subjects will be enrolled (assigned in the IVRS) and will meet the protocol defined 
IUS insertion failure, which is when, after contact with the cervical os by the inserter,  
completion of IUS insertion is not achieved.  However, some of these insertion failures 
are unrelated to the study IUS or inserter and such cases will not be analyzed as insertion 
failures.  Examples of such situations include, but are not limited to: 

withdrawal of consent after enrollment and before IUS placement

cervix could not be visualized

inserter became contaminated

subject could not tolerate sounding

uterus could not be sounded

uterus sounded to < 5.5 cm

enrolled but determined not to be eligible before IUS placement
Retrieved from the Medicines360 Veeva EDMS on 27 Sep 2023 by 


Medicines360 
Statistical Analysis Plan 
M360-L102 
02 October 2017 
Page 35 of 38 

prior IUD in uterus could not be removed.
Subjects who had a failed first insertion but never came back for a second attempt are 
considered to be a failed insertion and not a discontinuation due to withdrawal of consent 
or lost to follow-up.   
11.9  Continuation, Expulsion, and Removal Rates 
Cumulative rates of IUS continuation, expulsion, and safety-related removal at 6 months, 
Years 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10 will be summarized.  Time to event will be calculated 
as the date of continuation/expulsion/removal minus the date of IUS insertion plus one.  
Subjects without a continuation/expulsion/removal will be censored at the last contact 
date (as described in Section 5.4) and failure time will be calculated as the last contact 
date minus the date of IUS insertion plus one. Subjects who report an expulsion that is 
not confirmed by the study site will be censored.  The safety-related removal rates may 
also be summarized by MedDRA preferred term in the same manner. 
Expulsion rates including analysis of complete and partial expulsions by inserter type, 
parity and duration of use (by year) in the Safety Population will also be summarized.  
11.10  Fertility Rates Post-Removal 
Cumulative fertility rates for each month of the first year following IUS removal for 
women who desire pregnancy or who do not use any contraception and become pregnant, 
based on the Final Status CRF, will be summarized by treatment group.  Time to event 
will be calculated as the date of pregnancy minus the date of removal plus one.  Subjects 
who do not get pregnant will be censored at 12 months and failure time will be calculated 
as 12 months date minus the date of removal plus one.  Subjects who initially desire to 
become pregnant after IUS discontinuation but do not complete a full 12 months before 
discontinuing the effort to achieve pregnancy will be excluded from the analysis.   
11.11  Return to Menses 
The time to return to menses for each month following IUS removal for those women 
who are using non-hormonal contraceptive methods or no contraception following IUS 
discontinuation will be summarized by treatment group.  Time to event will be calculated 
as the date of menstruation minus the date of removal plus one.  Subjects who do not 
have a return of menstruation will be censored at the date of diagnosis for secondary 
amenorrhea and failure time will be calculated as the date of diagnosis for secondary 
amenorrhea minus the date of removal plus one.   
Retrieved from the Medicines360 Veeva EDMS on 27 Sep 2023 by 


Medicines360 
Statistical Analysis Plan 
M360-L102 
02 October 2017 
Page 36 of 38 
11.12  Pelvic and Breast Examinations 
Any abnormal pelvic or breast findings will be included in the adverse event reporting. 
11.13  Clinical Laboratory Evaluation 
11.13.1  Hemoglobin 
Hemoglobin will be summarized using descriptive statistics at Baseline, Month 12, 
Month 60 and the Final Visit.  Final Visit is defined as either the early discontinuation or 
study treatment completion visit.  Baseline is defined as the last non-missing value prior 
to IUS insertion.  However, if a baseline value is not obtained due to protocol deviation 
or laboratory error, a Month 1 visit or an Unscheduled Visit within the Month 1 visit 
window will be used as Baseline in a sensitivity analysis.  Changes from Baseline at 
Month 12, Month 60 and the Final Visit will also be summarized.  
11.13.2  Chlamydia and Gonorrhea Evaluations 
The frequency and percentage of Chlamydia and gonorrhea results will be summarized 
for each applicable visit by treatment group.  Similar to hemoglobin analyses, if a 
baseline value is not obtained due to protocol deviation or laboratory error, a Month 1 
visit or an Unscheduled Visit within the Month 1 visit window will be used as Baseline in 
a sensitivity analysis.  In addition, the frequency and percentage of subjects with a change 
in sexual partners will be summarized. 
11.13.3  Pap Tests 
The frequency and percentage of Pap test results will be summarized for each applicable 
visit by treatment group. 
11.13.4  Serum Chemistry and Urine Pregnancy Tests 
Serum chemistry and urine pregnancy tests will be listed by treatment group and subject. 
11.14  Endometrial Thickness 
Endometrial thickness at baseline and after 1, 5 and 10 years of LNG20 use will be 
summarized using the ET population.  Changes from baseline will also be summarized. 
Baseline is defined as the last non-missing value prior IUS insertion. 
Retrieved from the Medicines360 Veeva EDMS on 27 Sep 2023 by 


Medicines360 
Statistical Analysis Plan 
M360-L102 
02 October 2017 
Page 37 of 38 
11.15  Vital Signs 
Vital signs, blood pressure and weight, will be summarized using descriptive statistics at 
baseline and at each post-baseline time point.  Changes from baseline will also be 
summarized.  Baseline is defined as the last non-missing value prior to IUS insertion. 
Temperature and height will only be presented in listings. 
Retrieved from the Medicines360 Veeva EDMS on 27 Sep 2023 by 


Medicines360 
Statistical Analysis Plan 
M360-L102 
02 October 2017 
Page 38 of 38 
12. REFERENCES
1. Benda et al. Sample Size Calculation for Clinical Studies on the Efficacy of a New
Contraceptive Method.  Biometrical Journal 2004;1:141-150.
2. Gerlinger et al. Recommendation for confidence interval and sample size
calculation for the Pearl Index. The European Journal of Contraception and
Reproductive Health Care 2003; 8:87–92
Retrieved from the Medicines360 Veeva EDMS on 27 Sep 2023 by